IROKO PHARMACEUTICALS INC.
One Kew Place, 150 Rouse Boulevard
Philadelphia, PA 19112
July 31, 2013
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7010
Re: | Iroko Pharmaceuticals Inc. |
Request to Withdraw
Registration Statement on Form F-1 (Reg No. 333-189428)
Ladies and Gentlemen:
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended, Iroko Pharmaceuticals Inc. (the Company) hereby requests that the Securities and Exchange Commission (the Commission) consent to the withdrawal, effective as of the date hereof or at the earliest possible practicable date hereafter, of its Registration Statement on Form F-1 (Registration No. 333-189428), together with all amendments and exhibits thereto (collectively, the Registration Statement).
The Company is requesting withdrawal of the Registration Statement due to the Companys decision not to proceed with the initial public offering contemplated by the Registration Statement. No securities were sold pursuant to the Registration Statement.
The Company also requests that, in accordance with Rule 457(p) of the Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use pursuant to such Rule.
Very truly yours, | ||
IROKO PHARMACEUTICALS INC. | ||
By: | /s/ Moji Amanda James | |
Moji Amanda James | ||
Senior Vice President, General Counsel | ||
and Secretary |